A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Clinical trial NCT06614192 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06614192
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-08
- Primary completion
- 2027-08-01
- Enrollment
- 74
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.